Can patients with leukemia be completely cured by taking giritinib (segatan)?

Gilteritinib (Gilteritinib) is an oral tyrosine kinase inhibitor targeting FLT3 mutations. It is mainly used to treat patients with relapsed or refractory acute myeloid leukemia (AML). Its mechanism of action blocks the proliferation and survival of leukemia cells by inhibiting the FLT3 signaling pathway, thereby controlling the progression of the disease. However, currently, giritinib is mainly used for disease control and survival prolongation, and it cannot guarantee complete cure for all patients.

Clinical studies have shown that giritinib can achieve complete remission (CR< span>) or partial response (PR), improving progression-free survival (PFS) and overall survival (OS). Especially for patients who cannot tolerate intense chemotherapy or who have relapsed or refractory disease, giritinib provides an effective treatment option. However, it is important to note that even after remission, leukemia can still relapse, and the chance of complete cure varies depending on the patient's genetic background, age, and severity of the disease.

In actual treatment, giritinib is often used in combination with other treatments, such as chemotherapy or hematopoietic stem cell transplantation, to improve the cure rate. Combination therapy can enhance the killing power of leukemia cells and reduce the risk of drug resistance, but the patient's physical condition and potential side effects still need to be evaluated. Doctors will develop treatment courses and combination plans based on individualized conditions in order to achieve the best results.

In general, giritinib has significant efficacy in the treatment of leukemia and can help some patients achieve remission and extend survival, but single drug use does not mean complete cure. Patients should use giritinib under the guidance of a professional doctor, and regularly review blood routine and bone marrow conditions to monitor efficacy and early detection of recurrence risk. At the same time, the treatment plan should be adjusted according to the doctor's recommendations to strive for the best treatment effect.

Reference materials:https://www.drugs.com/